DNAPrint Launches Research to Enhance Law Enforcement Forensics Technology With 3D Biometric Capability

DNAPrint Launches Research to Enhance Law Enforcement Forensics
Technology With 3D Biometric Capability 


SARASOTA, Fla., June 10  /PRNewswire-FirstCall/ -- DNAPrint genomics, Inc.
(OTC:DNAP) (BULLETIN BOARD: DNAP)  (the "Company") today announced that it has
begun research on developing 3D biometric applications for the Company's
DNAWitness(TM) law enforcement forensics technology.

"The ability to interpret whether DNA recovered at a crime scene can reveal
anything about a person's likely facial features and other attributes of
physical appearance would be a significant tool for forensic investigators and
a valuable enhancement for our DNAWitness product," stated DNAPrint President
and Chief Executive Officer Richard Gabriel.

The aim of the project is two-fold, according to Dr. Mark Shriver, Associate
Professor of Biology Anthropology at Penn State University, where the research
is being conducted. "We want to provide better tools for forensics
professionals to infer physical appearance indirectly through assessment of
BioGeographical (or genomic) Ancestry and to discover new genes that underlie
specific phenotypes or physical features," he stated.

DNAPrint's anthropometric databases currently are built from and/or comprised
of 2-dimensional digital photographs. One of the research project's goals is to
integrate new 3D technology purchased by DNAPrint from Atlanta- based 3dMD (
http://www.3dmd.com/ ) with DNAWitness. The 3D application is also expected to
enable anthropometric features to be documented with the precision required for
sensitive and comprehensive genome research.

DNAPrint's DNAWitness technology for law enforcement analyzes DNA recovered
from a crime scene. In August 2004 the Company introduced RETINOME(TM) for
determining human iris (eye) color from DNA samples. DNAPrint also recently
introduced a DNAWitness test kit that enables forensics experts to conduct
their own tests in their own facilities without sending recovered DNA back to
the Company for analysis.

DNAWitness forensics technology is the only testing method available with
predictive capability that can identify the percentage of a person's genetic
makeup among four possible groups -- Sub-Saharan African, Native American, East
Asian and Indo-European plus the recent addition of Northern European, Middle
Eastern, Mediterranean and Indo (Pakistan and India).  This broadens an
investigator's ability to provide a description of a person of interest. It is
a valuable investigative tool for analyzing DNA recovered at a crime scene
because it narrows the search for potential suspects, reducing cost and time in
making an apprehension.

Dr. Shriver is conducting the research as part of a population genomic study at
Penn State entitled "The Genetics of Human Pigmentation, Ancestry and Facial
Features" and is utilizing the 3D technology in his laboratory to document
anthropometric facial-cranial traits of research subjects. This information is
valuable for forensic scientists in reconstructing physical characteristics
from crime scene DNA, but is also useful for geneticists in designing studies
aimed at identifying the underlying genes.

"Our common goal remains the same, to help investigators solve cases," Mr.
Gabriel stated. "We have now participated in more than 80 law enforcement
cases, eliminating speculation and changing the direction and focus of many
investigations. Upon completion of beta testing some time this year on our new
DNAWitness(TM) test kit, forensics experts in every crime laboratory in the
world will have easy access to our technology."

DNAPrint has been at the forefront of the effort to optimize Admixture Mapping
(AM) methodology using eye, hair and skin pigmentation (which are relatively
easy to measure) as model systems.  In the journal Genetics in 2003, DNAPrint
scientists described one such gene called OCA2 as the primary human iris color
gene, and Dr. Shriver has identified a number of genes that may be involved in
skin pigmentation.  Until now, the genetics of facial features has been very
difficult to investigate as geneticists have been limited by older technologies
that were not capable of precise objective anthropometric measurement.

About DNAPrint genomics, Inc.

DNAPrint genomics, Inc. ( http://www.dnaprint.com/ ) is a developer of genomic
and pharmaceutical products and services focused on applications for new drugs,
forensics technology for the law enforcement market and consumer products for
individuals interested in learning their family heritage. DNAPrint products
include ANCESTRYbyDNA(TM), EURO-DNA(TM) and DNAWitness(TM) and are available by
contacting the company or visiting our web site. Other products in development
include OVANOME(TM), a test for predicting a cancer patient's response to
TAXOL/Carboplatin treatment; STATINOME(TM), a test for predicting the response
to cholesterol lowering medicines known as Statins and "Super EPO" and the
Company's first drug development project, an erythropoietin dimer used to treat
kidney dialysis patients.

Forward-Looking Statements

All statements in this press release that are not historical are forward-
looking statements. Such statements are subject to risks and uncertainties that
could cause actual results to differ materially from those projected,
including, but not limited to, uncertainties relating to technologies, product
development, manufacturing, market acceptance, cost and pricing of DNAPrint's
products, dependence on collaborations and partners, regulatory approvals,
competition, intellectual property of others, and patent protection and
litigation. DNAPrint genomics, Inc. expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any forward-
looking statements contained herein to reflect any change in DNAPrint's
expectations with regard thereto or any change in events, conditions, or
circumstances on which any such statements are based.

   Company Contact:
   Richard Gabriel
   President and CEO
   941-366-3400
        -or-
   Ron Stabiner
   The Wall Street Group, Inc.
   212-888-4848


DATASOURCE: DNAPrint genomics



CONTACT:  Richard Gabriel, President and CEO, DNAPrint genomics,

[phone]; or Ron Stabiner, The Wall Street Group, Inc.,

[phone], for DNAPrint genomics



Web site:  http://www.dnaprint.com/

http://www.3dmd.com/ 

Copyright